- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02978482
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in Combination With Tremelimumab in Chinese Patients With Advanced Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Changchun, China, 130012
- Research Site
-
Changchun, China, 130000
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Male or female, aged at least 18 years
- For Phase 1 PK cohort:
Patients with histologically or cytologically confirmed advanced and/or metastatic solid tumors other than HCC refractory or intolerable to existing standard of treatment
For Phase 2 cohort:
For nasopharyngeal carcinoma:
Patients with histologically or cytologically confirmed nasopharyngeal carcinoma must have locally advanced or metastatic disease progressed on or after at least 1 chemotherapy regimen with or without radiotherapy.
- ONLY FOR PHASE 2 PORTION: mandatory tumor sample
- No prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
- Life expectancy ≥12 weeks at Day 1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- At least 1 lesion that can be accurately measured at baseline, and that is suitable for repeated measurements as per RECIST 1.1 guidelines.
- Adequate organ and marrow function
- Hemoglobin ≥9 g/dL Absolute neutrophil count ≥1.0 × 109 /L Platelet count ≥75 × 109/L Total serum bilirubin ≤1.5×upper limit of normal (ULN) ALT and AST ≤2.5×ULN; for patients with hepatic metastases, ALT and AST ≤5×ULN Calculated creatinine clearance >40 mL/min as determined by Cockcroft-Gault (using actual body weight), or by measured 24-hour urine collection for determination of creatinine clearance.
- Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients.
- Exclusion Criteria:
- Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable. Note: Local treatment of isolated lesions for palliative intent is acceptable (eg, local surgery or radiotherapy).
- Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment. If sufficient washout time has not occurred due to the schedule or PK properties of an agent, a longer washout period will be required, as agreed upon by AstraZeneca and the Investigator.
- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- History of allogenic organ transplantation
- Any unresolved toxicity National Cancer Institute (NCI) CTCAE Version 4.03 Grade ≥2 from previous anticancer therapy
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc).
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- History of another primary malignancy
- History of leptomeningeal carcinomatosis
- Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 14 days prior to study treatment.
- QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated.
- History of active primary immunodeficiency
- Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus .
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (MEDI4736) or tremelimumab.
- Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP.
- Female patients who are pregnant or breast-feeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab (MEDI4736) plus tremelimumab combination therapy or 90 days after the last dose of durvalumab (MEDI4736) monotherapy.
- Known allergy or hypersensitivity to IP or any IP excipient, or to other humanized mAbs
- Prior randomisation or treatment in a previous durvalumab (MEDI4736) and/or tremelimumab clinical study regardless of treatment arm assignment
- NSCLC patients have history of interstitial lung disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: durvalumab
durvalumab alone
|
durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
|
Experimental: durvalumab+tremelimumab
durvalumab plus tremelimumab
|
20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax)
Time Frame: approximately 6 months after the last evaluable patient in Phase 1 portion is first dosed
|
Only for phase 1 portion of the study
|
approximately 6 months after the last evaluable patient in Phase 1 portion is first dosed
|
Trough plasma concentration (Ctrough)
Time Frame: approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
|
Only for phase 1 portion of the study
|
approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
|
Area under the plasma drug concentration-time curve from time zero to Day 28 post-dose (AUC 0-28)
Time Frame: approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
|
Only for phase 1 portion of the study
|
approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
|
Adverse event
Time Frame: Approximately 12 months after the last evaluable patient from Ph 1 is 1st dosed or the last patient has withdrawn from study or the study discontinued by Sponsor
|
Approximately 12 months after the last evaluable patient from Ph 1 is 1st dosed or the last patient has withdrawn from study or the study discontinued by Sponsor
|
|
Objective response rate (ORR)
Time Frame: Approximately 12 months after the last evaluable patient is dosed, or the last patient has withdrawn from the study or the study is discontinued by the sponsor.
|
Only for phase 2 portion of the study (Phase 2 part withdrawn without initiation)
|
Approximately 12 months after the last evaluable patient is dosed, or the last patient has withdrawn from the study or the study is discontinued by the sponsor.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-drug antibody (ADA)
Time Frame: approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor
|
approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor
|
|
Anti-drug antibody neutralizing antibodies (ADA nAB)
Time Frame: approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor
|
approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor
|
|
Complete response/Partial response/Stable disease/Progressive disease
Time Frame: approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
|
Only for phase 1 portion of the study
|
approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
|
Overall survival (OS)
Time Frame: approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor
|
Only for phase 2 portion of the study (Phase 2 part withdrawn without initiation)
|
approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PD-L1 status
Time Frame: through study completion, an average of 2 years
|
Only for phase 2 portion of the study (Phase 2 part withdrawn without initiation)
|
through study completion, an average of 2 years
|
CD8+ T cells
Time Frame: through study completion, an average of 2 years
|
Only for phase 2 portion of the study (Phase 2 part withdrawn without initiation)
|
through study completion, an average of 2 years
|
IFNγ
Time Frame: through study completion, an average of 2 years
|
Only for phase 2 portion of the study (Phase 2 part withdrawn without initiation)
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Urban Scheuring, AstraZeneca GMD IO, Melbourn Science Park, Melbourn, Royston, Hertfordshire, SG8 6HB, UK
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D419AC00006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignancy
-
National University Hospital, SingaporeCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
John SarantopoulosNo longer availableAdvanced MalignancyUnited States
-
AstraZenecaCompletedAdvanced Solid Tumor | Advanced Solid MalignancyJapan
-
Cytovation ASMerck Sharp & Dohme LLCActive, not recruitingAdvanced Solid Tumor MalignancyNetherlands, France, Spain
-
Kling Biotherapeutics B.V.RecruitingAdvanced Solid Tumor MalignancyBelgium, Netherlands
-
NewLink Genetics CorporationTerminatedAdvanced Solid Tumor MalignancyUnited States
-
Leonard ApplemanAstraZenecaCompletedAdvanced Incurable Solid MalignancyUnited States
-
SCRI Development Innovations, LLCNovartisCompletedAdvanced Malignancies | Refractory MalignancyUnited States
Clinical Trials on durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
Hark Kyun KimRecruiting
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
MedImmune LLCCompletedAdvanced Solid TumorsUnited States, France, Spain, Switzerland
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of